Private Induced Pluripotent Stem Cell Banking-Advantages Over Cord Blood Banking
CET is partnering with the John Paul II Medical Research Institute (JP2MRI) to launch a private bank of induced pluripotent stem cells (iPSC) from clients who wish to produce a personalized and lifelong iPSC for future diagnostics, research and therapeutic benefits. This new iPSC bio-banking services is being established to replace the shortcomings of private cord blood banking with a new milestone in regenerative medicine based on the first described virus-free and oncogene-free iPSC. The new iPSC bio-bank will also allow the consumer to create a personalized iPSC from peripheral blood. Thus, the consumer can still create a lifelong pluripotent stem cell even if they failed to store their cord blood.
This new milestone in iPSC technology will offer diagnostic and medical research opportunities, along with potentially safer forms of future autologous iPSC-derived therapies for the consumer. This new service is being created based on published scientific studies conducted by CET, JP2MRI and other academic partnerships (1,2).
In response to this technical milestone and in response to public requests, CET has initiated a waiting list from consumers who would like to create a personalized iPSC from privately banked cord blood. Also, consumers who are less than 40 years of age and healthy can also sign up on this waiting list to create a iPSC from a peripheral blood sample.
CET is currently offering an introductory PROMOTION to those who sign up on the waiting list by providing a 20 percent discount on this service.
For further information on CET's iPSC technology, go to the following link.
To contact CET to obtain further information on this iPSC bio-bank service, go to this link.
References: